Skip to main content Skip to navigation

Personalised Medicines International Symposium 5th July 2006

3rd AC21 Research Festival

From Genes to Patients:
New Perspectives on Personalised Medicines

International One Day Symposium Wednesday 5th July, 2006

Medical Teaching Centre, Warwick Medical School, University of Warwick, UK

The Symposium was supported by a wtlogo Award.


Fig. 1. Commission on human medicines chair Professor Sir Gordon Duff presents

the best poster award to Dr Mariluz Rodriguez, N Ireland

Symposium outline

A major opportunity to improve treatment of patients arises from the fact that treatment response can be influenced by individual differences in tissue regulation and drug effectiveness. Differences in treatment response may for example arise from genetic and resulting proteomic differences in drug transporters, receptors and in pathways for drug action. Occurrence of adverse drug reactions (ADRs) can also be associated with genetic differences linked to poor drug metabolism. Pharmacogenetic and pharmacoproteomic profiling thus carries the potential to improve earlier selection of effective drug treatments, to reduce incidence of ADRs and to reduce pressures on medical services. The aim of the symposium was to consider ways in which recent developments in genomics and in proteomics can applied to effective personalised medicine profiling in clinical practice and to consider issues important in implementing into practice the necessary health technology innovations.






Fig. 2. Top left: Professor Robert Freedman, Head Biological Sciences, University of Warwick, introducing the first session; top centre: Dr Duncan mchale, Pfizer; top right: Dr Kevin Cheeseman, Astrazeneca; lower left, Dr guy Barker, warwick HRI; lower left, Professor Jan dumanski, university of birmingham, alabama & university of uppsala.

Speakers, discussants and chairs: click on links for information on speakers and their abstracts


fig. 3. top left: Dr David Elsy (l), Withers & rogers LLP, Dr Frank vince, Coventry & professor donald singer (r), symposium chair, University of Warwick; top centre: Professor Vilhjálmur Árnason, Reykjavik; top right: professor ruth chadwick, cardiff; lower left: professor ralph edwards, who, uppsala; lower centre: professor magnus ingelman-sundberg, karolinska, stockholm; lower right: professor Sir gordon duff, chair, commission on human medicines.


Fig. 4. Poster sessions


click on the links to view the abstracts of the posters presented on the day of the symposium

1. Allele and genotype frequencies of DPYD*2A and TYMS in a Turkish population. 

Sinan H. Süzen, Nazan Yüce, Gülçin Güvenç, Yalçýn Duydu
Department of Toxicology, Faculty of Pharmacy, Ankara University, Tandoðan, Ankara, 06100, Turkey
2. Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A 

Yasuyuki Goto, Yoshiko ishida, Takaaki Kondo, Mio Kurata, Kazuko Nishio, Sayo Kawai, Tomo Osafune, Mariko Naito and Nobuyuki Hamajima
Department of Preventive Medicine / Biostatistics and Medical Decision Making, Nagoya University Graduate School of Medicine.


3. Gene therapy using VEGF-E/human PlGF chimeric genes for therapeutic angiogenesis in experimental animal model  

Takahisa Kondo, MD, PhD*; Natsuo Inoue, MD*; Koichi Kobayashi, MD*; Mika Aoki, BS1; Masabumi Shibuya, MD, PhD**; Toyoaki Murohara, MD, PhD*
*Department of Cardiology, Nagoya University Graduate School of Medicine; **Department of Cancer Biology, The Institute of Medical Science, The University of Tokyo


4. Neutralization of hepatocyte growth factor inhibits human cytomegalovirus replication in human lung fibroblast

Walid Basha1 and Junji Tanaka2
1Department of Medical Lab. Science, Faculty of Allied Medical Sciences, Arab American University-Jenin, Jenin, Palestine, 2Department of Laboratory Science, School of Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa, Japan

5. Application of biochip array technology to the non-invasive qualitative simultaneous detection of DNA alterations in colorectal cancer. 

Mariluz Rodriguez, S. Peter FitzGerald, Helena Murray, R. Ivan McConnell, Roisin Molloy.
Randox Laboratories Ltd. 55, Diamond Road, Crumlin, Northern Ireland, UK.

6. The Magic Tag Kit: Immobilisation and Screening of Bioactives 

Andrew Clark, Suzanne Dilly, Andrew Marsh and Paul Taylor
Department of Chemistry, University of Warwick, CV4 7AL


7. Association between SNPs in Adenosine Receptor 2a (ADORA2a) and Adverse Drug Reactions (ADRs) in Methotrexate Treated Rheumatoid Arthritis Patients 

L.F. Mack1, S.L. Hider1, D. Armstrong2, M. Shadforth3, I.N. Bruce1, W. Thomson1
1 arc Epidemiology Unit, University of Manchester, 2 Rheumatology Department, Musgrave Park Hospital, Belfast, 3 Rheumatology Department, University Hospitals of North Staffordshire.

8. Role of oxidant stress in human endothelial cells

*^Baijun Kou, *Junlong Zhang, *Donald RJ Singer*CSRI,
*Warwick Medical School, University of Warwick, CV2 2DX;^Medical School, Sheffield University, S10 2RX

9. Reduced risk for endothelial dysfunction in diabetes: is correcting hyperglycaemia enough? 

Sevasti Zervou1, David Epstein2, Stella Pelengaris1 and Michael Khan1
1Department of Biological Sciences, and 2Department of Mathematics, University of Warwick, Coventry CV4 7AL, UK

10. Relationship of alpha-1-antitrypsin serum levels and genetic variants in patients with phenotypic alpha-1-antitrypsin deficiency 

Sarojini Pandey and Dimitris Grammatopoulos
University of Warwick, Coventry CV4 7AL, UK


11. Health Technology Assessment (HTA) of Non-Invasive RhD Testing 

Ala Szczepura, Leeza Osipenko, Karoline Freeman,
Clinical Sciences Warwick Medical School Coventry, UK CV4 7AL.


12. Exploring patients’ and healthcare professionals’ views of pharmacogenetic testing

Emily A Fargher1, Charlotte Eddy2, Katherine Payne1, Karen Tricker1, Rachel A Elliott3, Faieza Qasim4, Ian Bruce4, Jon Shaffer5, Christopher Griffiths5, Kieran Moriarty6, Cath Pearson6, and William Newman1&2.

1North West Genetics Knowledge Park, The University of Manchester, Manchester, UK; 2Clinical Genetics, St Mary’s Hospital, Manchester, UK; 3School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Manchester, UK; 4Central Manchester & Manchester Children's University Hospitals NHS Trust, Manchester, UK; 5Salford Royal Hospitals NHS Trust, Salford, UK; 6Bolton Hospitals NHS Trust, Bolton, UK.

*MRC Fellow in Health Services Research School of Health and Related Research, University of Sheffield, Regent Court, 30, Regent Street, Sheffield, S1 4DA; **Professor of Health Economics, Warwick Medical School, University of Warwick, Coventry CV4 7AL; ***Professor of Public Health, Institute of Health Sciences and Public Health Research, University of Leeds


14. Taking the fight to the superbugs – searching for new antibiotics 

Adair Richards
Molecular Organisation and Assembly of Cells Doctoral Training Centre, University of Warwick


15. Preliminary Phenotyping Studies in the TARGET Project: Thiopurine Methyltransferase (TPMT) Measurements and Azathioprine Metabolite Profiling 
Jane E Alder1, Gary P. Sidgwick1, William Newman1&2, Sudeep P. Pushpakom3, Karen Tricker1, Katherine Payne1 Emily A Fargher1, Kay Poulton2, Faieza Qasim2, J Brian Houston1, Rachel A Elliott 1, Robert G Elles3, David W Ray1, John Shaffer4, Christopher E Griffiths1, Ian N Bruce1, Steven A Roberts1, Julie Andrews1 and William E Ollier1
1The University of Manchester, Oxford Road, Manchester M13 9PL; 2Central Manchester & Manchester Children's University Hospitals NHS Trust; 3National Genetics Reference Laboratory, St Mary's Hospital, Manchester; 4Salford Royal Hospitals NHS Trust

Local Organizing Committee

Professor Wendy Currie, Warwick Business School
Dr Dimitris Grammatopoulos, Molecular Diagnostics
Pam Magee, Chief Pharmacist
Professor Christopher McCabe, Health Economics
Dr Daniel Mitchell, Pharmacogenomics
Dr Teresa Pawlikowska, Primary Care
Professor Donald Singer, Clinical Pharmacology & Therapeutics Symposium Leader
Professor Margaret Thorogood, Epidemiology
Dr Junlong Zhang, Molecular Endocrinology

Key topics included:

  • Genetic targets: CYP enzymes, drug transporters; receptors, cell signalling

  • Genetic methods: genotyping; gene mapping; SNP vs. CNP studies

  • Proteomic approaches to drug discovery

  • Clinical cohort phenotyping and follow up

  • Pharmacovigilance platforms: expert systems and cross-cultural issues

  • Bio-informatics

  • Ethical considerations

  • Intellectual Property and Patents

  • Health economics of implementing personalised gene testing

  • Patients’ & users’ perspectives

  • Role of regulatory authorities

  • Role of biotechnology industry

  • Role of pharmaceutical industry

  • Role of Small to Medium-sized Enterprises [SMEs]

Who attended?

This symposium was of interest to:

  • Biotechnology industries

  • Clinicians

  • Ethicists

  • Experts in Intellectual Property and Patents

  • Health economists

  • Health media

  • Pharmaceutical professionals

  • Pharmacists and other interested health professionals

  • Policy makers

  • Regulatory Authorities

  • Scientists interested in genetics, genomics, proteomics, glycobiology and new therapeutic targets

  • Statisticians, include experts in risk analysis

Shakespeare Social Programme

Associated International Research Festival

AC21 3rd Biennial International Forum, July 4-6, 2006: See Research Festival link for further information on Symposia on Health Wealth & Nutrition, Nanotechnology, Mathematics and Beyond, Sustainable Manufacturing, Global HE Research, Corporate Responsibility, English in Higher Education

Clinical Pharmacology


International symposium Home Page

Progress on Personalizing Medicines

25th September 2008







fig. 6. University of Sydney Pro-Vice Chancellor Professor John Hearn discussing Stem Cell Therapy


Personalised Medicines Programme

International Scientific Board

Local Organising Committee

Clinical Pharmacology Newsletters

integrated personalised medicines - ipermed